Form 4: ImmunityBio Director Michael Blaszyk Receives Stock Options
Statement of Changes in Beneficial Ownership
Director Michael D. Blaszyk was granted 65,600 stock options in ImmunityBio, Inc. as part of the company's 2025 Equity Incentive Plan.
Summary
- Director Michael D. Blaszyk received a grant of 65,600 stock options on June 9, 2026.
- The options have an exercise price of $7.25 per share.
- The options are scheduled to vest in full on the earlier of June 9, 2027, or the day before the next annual meeting of stockholders, provided the director remains a service provider.
- The expiration date for these options is June 9, 2036.
Sentiment
Score: 5
Explanation: StockSavvy.ai views this as a routine administrative filing regarding director compensation, which is neutral in terms of immediate market impact.
Positives
- Alignment of director interests with long-term shareholder value through equity-based compensation.
Negatives
- The grant results in potential future dilution for existing shareholders.
Risks
- Vesting is contingent upon the director's continued service to the company.
- The value of the options is subject to market volatility and the future performance of IBRX stock.
Future Outlook
The filing does not provide forward-looking financial guidance, focusing solely on the disclosure of director equity compensation.
Industry Context
StockSavvy.ai notes that equity grants to board members are standard practice in the biotechnology sector to incentivize oversight and long-term strategic commitment, particularly for companies in the clinical development stage.
Comparison to Industry Standards
- The use of a one-year cliff vesting period for director options is consistent with standard corporate governance practices for mid-cap biotech firms.
- The grant size is typical for non-executive director compensation packages in the industry.
Corporate Governance
| Change Type | Description | Effective Date | Impact Assessment |
|---|---|---|---|
| Power of Attorney | Filing of a Power of Attorney authorizing specific individuals to execute SEC filings on behalf of the director. | 2025-11-20 | Administrative update to streamline regulatory compliance. |
Stakeholder Impact
- Shareholders may experience minor dilution upon the eventual exercise of these options.
Next Steps
- Vesting of options on June 9, 2027, or the day before the next annual meeting.
Key Dates
| Date | Description |
|---|---|
| 2025-11-20 | Date of Power of Attorney execution. |
| 2026-06-09 | Date of option grant and earliest transaction. |
| 2027-06-09 | Vesting date for the stock options. |
| 2036-06-09 | Expiration date for the stock options. |
Keywords
ImmunityBio, IBRX, Form 4, Stock Options, Director Compensation, Equity Incentive Plan
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.